HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock

 HeartWare International, Inc. Announces Pricing of Public Offering of Common
                                    Stock

PR Newswire

FRAMINGHAM, Mass. and SYDNEY, March 12, 2013

FRAMINGHAM, Mass. and SYDNEY, March 12, 2013 /PRNewswire/ -- HeartWare
International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today the
pricing of a public offering of 1,500,000 shares of common stock at a price
per share of $86.45 pursuant to an effective shelf registration statement
filed with the Securities and Exchange Commission ("SEC"). HeartWare also
granted the underwriters an option to purchase up to an additional 225,000
shares to cover over-allotments, if any.

HeartWare intends to use the net proceeds from the offering for working
capital and general corporate purposes, including, but not limited to,
research and development, expansion of manufacturing capabilities, selling and
marketing activities, capital investments in information systems, facilities
and infrastructure, and general and administrative support functions to
support growth and the acquisition or licensing of or investment in
complementary products, technologies or businesses.

J.P. Morgan Securities LLC is acting as the sole book-running manager for the
offering. Canaccord Genuity Inc., Credit Suisse Securities (USA) LLC and
Lazard Capital Markets LLC are acting as co-managers of the offering. Perella
Weinberg Partners served as independent capital markets advisor to HeartWare
on this offering.

The offering does not require the prior approval of HeartWare's stockholders
under the requirements of the Australian Stock Exchange.

This press release shall not constitute an offer to sell or a solicitation of
an offer to buy any securities nor shall there be any sale of these securities
in any state in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of such state. The
issuer has filed a registration statement (including a prospectus) with the
SEC for the offering to which this communication relates. The offering will be
made only by means of a prospectus and the related prospectus supplement.
Before you invest, you should read the prospectus and the related prospectus
supplement and any other document HeartWare has filed with the SEC for more
complete information about HeartWare and the offering. You may get these
documents for free by visiting EDGAR on the SEC Website at www.sec.gov.
Alternatively, copies of the prospectus and the related prospectus supplement
can be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by
calling 1-866-803-9204.

About HeartWare International
HeartWare International develops and manufactures miniaturized implantable
heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients
suffering from advanced heart failure.

Forward-Looking Statements
This announcement contains forward-looking statements that are based on
management's beliefs, assumptions and expectations and on information
currently available to management. All statements that address operating
performance, events or developments that we expect or anticipate will occur in
the future are forward-looking statements, including without limitation our
expectations with respect to the commercial launch of the HeartWare^®
Ventricular Assist System in the U.S., continued support from international
customers, progress of clinical trials and post-approval studies, regulatory
status, research and development activities, commercialization strategies and
the use of proceeds from this offering. Management believes that these
forward-looking statements are reasonable as and when made. However, you
should not place undue reliance on forward-looking statements because they
speak only as of the date when made. HeartWare does not assume any obligation
to publicly update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. HeartWare may not
actually achieve the plans, projections or expectations disclosed in
forward-looking statements, and actual results, developments or events could
differ materially from those disclosed in the forward-looking statements.
Forward-looking statements are subject to a number of risks and uncertainties,
including without limitation those described in Part I, Item 1A. "Risk
Factors" in our Annual Report on Form 10-K filed with the Securities and
Exchange Commission. We may update our risk factors from time to time in Part
II, Item 1A "Risk Factors" in our Quarterly Reports on Form 10-Q, Current
Reports on Form 8-K, or other filings with the Securities and Exchange
Commission.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864



SOURCE HeartWare International, Inc.

Website: http://www.heartware.com